Literature DB >> 8549278

Quinolones in the elderly.

T Bergan1.   

Abstract

Aging results in a number of physiological changes that can affect drug disposition; these include reduced gastric acidity, decreased intestinal motility, lower lean body mass, and reduction in renal function. The age-related decline in renal function is the most important of these factors when administering quinolones to elderly patients. Elimination half-life (t1/2) values are prolonged in proportion to the degree to which the compound is normally eliminated by the renal route. Thus, age-related increases in t1/2 occur to a greater degree with ofloxacin (80 to 90% renal elimination) than with ciprofloxacin, which is also excreted by the gastro-intestinal route. Norfloxacin, pefloxacin, and sparfloxacin may also be eliminated to a substantial degree by the transintestinal route, as their excretion is not substantially affected by severe renal impairment. Prolonged drug elimination in the elderly can result in an increased incidence of adverse effects. Ofloxacin causes a higher frequency of drug-related events in the elderly, presumably reflecting the prolonged serum t1/2 and higher serum concentrations, and consequently higher tissue levels in this age group. Indeed, dosage reduction is recommended when treating elderly patients with ofloxacin, but does not appear necessary on the basis of advanced age for ciprofloxacin, norfloxacin and pefloxacin.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8549278     DOI: 10.2165/00003495-199500492-00017

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  18 in total

1.  Transintestinal elimination of ciprofloxacin.

Authors:  R Rohwedder; T Bergan; S B Thorsteinsson; H Scholl
Journal:  Chemotherapy       Date:  1990       Impact factor: 2.544

2.  Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis.

Authors:  E Singlas; A Leroy; E Sultan; M Godin; B Moulin; A M Taburet; M Dhib; J P Fillastre
Journal:  Clin Pharmacokinet       Date:  1990-07       Impact factor: 6.447

3.  Pharmacokinetics of oral ciprofloxacin, 100 mg single dose, in volunteers and elderly patients.

Authors:  A P Ball; C Fox; M E Ball; I R Brown; J V Willis
Journal:  J Antimicrob Chemother       Date:  1986-05       Impact factor: 5.790

4.  Pharmacokinetics of ciprofloxacin in the elderly.

Authors:  A Bayer; A Gajewska; M Stephens; J M Stark; J Pathy
Journal:  Respiration       Date:  1987       Impact factor: 3.580

Review 5.  Pharmacokinetics in the elderly. Studies on ciprofloxacin.

Authors:  M Lebel; M G Bergeron
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

6.  Ofloxacin pharmacokinetics in renal failure.

Authors:  J P Fillastre; A Leroy; G Humbert
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

Review 7.  Pharmacokinetics of ciprofloxacin.

Authors:  T Bergan; A Dalhoff; R Rohwedder
Journal:  Infection       Date:  1988       Impact factor: 3.553

8.  Norfloxacin disposition after sequentially increasing oral doses.

Authors:  B N Swanson; V K Boppana; P H Vlasses; H H Rotmensch; R K Ferguson
Journal:  Antimicrob Agents Chemother       Date:  1983-02       Impact factor: 5.191

9.  Multiple-dose ciprofloxacin dose ranging and kinetics.

Authors:  M A Gonzalez; A H Moranchel; S Duran; A Pichardo; J L Magana; B Painter; G L Drusano
Journal:  Clin Pharmacol Ther       Date:  1985-06       Impact factor: 6.875

10.  Pharmacokinetics of ciprofloxacin: intravenous and increasing oral doses.

Authors:  T Bergan; S B Thorsteinsson; R Solberg; L Bjornskau; I M Kolstad; S Johnsen
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

View more
  1 in total

Review 1.  Quinolones in the aged.

Authors:  L E Nicolle
Journal:  Drugs       Date:  1999       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.